BTK inhibitor CC-292

{
  "id": "MLC-T-ONC-012144",
  "term": "BTK inhibitor CC-292",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.",
  "synonyms": [
    "BTK inhibitor AVL-292",
    "Bruton's tyrosine kinase inhibitor CC-292",
    "Bruton's tyrosine kinase inhibitor AVL-292"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/btk-inhibitor-cc-292/"
}